Home›Rheumatology› Tofacitinib reduces joint swelling in PAPA syndrome but does not reverse structural damage
Tofacitinib reduces joint swelling in PAPA syndrome but does not reverse structural damageTofacitinib May Reduce Joint Pain in PAPA Syndrome Cases
Frontiers in MedicinePublished August 19, 2026Study authors: Shuien He, Hao Deng, Jinghua Yang, Wenwen JiangDOI ↗Editorial oversight: Dr. Amelia Tan, PhD · Internal Medicine & Chronic Disease
AI-generated summary of the cited source, checked by automated accuracy review.
How we work
Share
Key Takeaway
Consider tofacitinib as a potential option for PAPA syndrome when IL-1 inhibitors are unavailable, but note it does not reverse structural damage.
This publication is a case report and literature review focusing on PAPA syndrome, a rare autoinflammatory disorder. The authors present the case of an 11-year-old Chinese boy with a 7-year history of recurrent, migratory arthritis and a heterozygous PSTPIP1 c.770A>G (p.Glu257Gly) variant. He was treated with tofacitinib at a dose of 3.5 mg twice daily.
After 2 months of treatment, the patient experienced a significant decrease in joint swelling and pain. However, radiographic assessment revealed irreversible structural damage, including bone demineralization, joint space narrowing, and osteophyte formation. The authors note that tofacitinib may reduce inflammation but does not reverse established joint damage.
The review component likely synthesizes prior literature on PAPA syndrome and treatment options, including IL-1 inhibitors, though specific details of the reviewed studies are not provided in the available information. The authors suggest that tofacitinib may be an alternative for patients who cannot access IL-1 inhibitors.
Limitations explicitly acknowledged include the short follow-up duration (2 months), the preliminary nature of the evidence, and the limited sample size inherent to a case report. Adverse events were not reported, and the long-term durability of response is not established.
For clinicians, this report offers low-certainty evidence that tofacitinib might reduce inflammatory symptoms in PAPA syndrome, but it should not be expected to reverse structural damage. The findings are hypothesis-generating rather than practice-changing.
How this fits prior evidence
This case report extends prior coverage on JAK inhibitors by suggesting a potential role for tofacitinib in PAPA syndrome, a rare autoinflammatory condition. It contrasts with prior findings that highlighted increased serious infection risk when tofacitinib is combined with other agents, as this report does not mention combination therapy or adverse events. It also aligns with earlier single-patient reports of tofacitinib efficacy in refractory conditions, reinforcing the need for cautious interpretation. The report addresses a gap by exploring tofacitinib in PAPA syndrome, but the low certainty and short follow-up limit its generalizability.
Doctors reported on an 11-year-old boy who had lived with a rare condition called PAPA syndrome for seven years. This condition causes repeated joint pain and inflammation. The boy was treated with tofacitinib, a medication often used for inflammatory conditions, because he could not access other common treatments like IL-1 inhibitors.
After two months of taking the medication, the boy showed significant improvements in his joint swelling and pain levels. However, the study also noted that the drug did not fix existing structural damage to his bones or joints. This type of damage is often permanent once it occurs.
Because this report only follows one patient over a short period, the evidence is very limited. It shows that tofacitinib might help manage active inflammation in patients with PAPA syndrome who have few other options. However, it does not reverse previous joint damage or prove long-term success for everyone.
What this means for you:
Tofacitinib may reduce current joint swelling in PAPA syndrome but cannot reverse existing structural bone damage.
Common questions
Can tofacitinib fix permanent joint damage in PAPA syndrome?
No, the study found that tofacitinib did not reverse existing structural damage such as bone demineralization or joint space narrowing. While it helped reduce active swelling and pain after two months, the physical damage to the joints remained.
Who is this treatment for?
This finding specifically concerns patients with PAPA syndrome, such as the 11-year-old boy in the report. It may be a helpful option for those who cannot access other treatments like IL-1 inhibitors.
Is this treatment proven to work long-term?
The evidence is currently limited because it is based on a single case study with a short follow-up period. More research is needed to determine how well the medication works over many years.
PAPA syndrome (pyogenic sterile arthritis, pyoderma gangrenosum, and acne) is a rare autosomal dominant autoinflammatory disorder caused by mutations in the PSTPIP1 gene. In pediatric patients, arthritis often precedes cutaneous manifestations by several years, leading to frequent misdiagnosis as septic arthritis. Treatment is challenging, with IL-1 inhibitors being the most pathophysiology-based first-line therapy, but their accessibility is limited by high costs. We reported an 11-year-old Chinese boy with a 7-year history of recurrent, migratory arthritis. Trio whole-exome sequencing identified a heterozygous PSTPIP1 c.770A>G (p.Glu257Gly) variant, classified as likely pathogenic. The father carried the same variant; he had experienced arthralgias in early childhood but became asymptomatic after age 10 without any treatment, demonstrating incomplete penetrance. This variant is extremely rare, reported in only one of 16 patients in the Eurofever registry, all of European descent, making this the first Asian case. Due to financial constraints, IL-1 inhibitors were inaccessible. Tofacitinib (3.5 mg twice daily, adjusted from adult dose based on body surface area) was initiated in February 2026. After 2 months, joint swelling and pain decreased significantly. As of July 10, 2026, no recurrence of joint swelling and pain had been observed during follow-up. However, radiography revealed irreversible structural damage (bone demineralization, joint space narrowing, osteophyte formation), and the patient still had limited mobility. Rehabilitation specialists advised against aggressive range-of-motion exercises and recommended home-based ultrasound and electrical stimulation to prevent muscle atrophy. Long-term follow-up is ongoing. PAPA syndrome should be considered in children with culture-negative, antibiotic-unresponsive recurrent arthritis, even without skin findings. Early genetic diagnosis can prevent unnecessary procedures. For patients who cannot access IL-1 inhibitors, tofacitinib may reduce inflammation, but it cannot reverse established joint damage. Given the relatively short follow-up duration, the long-term durability of response, safety, and impact of tofacitinib on disease progression remain to be determined. This report provides early, preliminary evidence of JAK inhibitor use in this population, contributing initial data to the limited Asian literature.
